Related Content
- Big Molecule WatchMay 16, 2025
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (ustekinumab-aekn) with STELARA (ustekinumab)
- Big Molecule WatchMay 16, 2025
Join Us! The Future of Biotech Regulation Webinar
- Big Molecule WatchMay 15, 2025
Third Circuit Affirms Rejection of AstraZeneca’s Challenges to IRA Drug Price Negotiation Program
- Big Molecule WatchMay 15, 2025
President Trump Issues Two Executive Orders Concerning the Affordability and Accessibility of Drugs
- Life Sciences PerspectivesMay 14, 2025
Antitrust Life Sciences Quarterly Update 2025 Q1
- Life Sciences PerspectivesMay 13, 2025
Most Favored Nation Drug Pricing Executive Order Resurrects Prior President Trump Policy
- InsightMay 13, 2025
Antitrust Life Sciences Quarterly Update 2025 Q1
- AlertMay 12, 2025
Most Favored Nation Drug Pricing Executive Order Resurrects Prior President Trump Policy
- Press ReleaseMay 19, 2025
Goodwin Represents Inozyme Pharma in $270 Million Acquisition by BioMarin to Strengthen Enzyme Therapy Business
- Press ReleaseMay 12, 2025
Goodwin Scales Life Sciences Practice in Boston with the Arrival of Partner Felipe Heiderich
- In the PressMay 6, 2025
Rare Disease Industry Awaits FDA Chief’s New Drug Pathway Plan (Bloomberg Law)
- In the PressMay 1, 2025
AI in Healthcare: Private Equity’s Next Frontier? (Real Deals)
- Press ReleaseMay 1, 2025
Kronos Bio To Be Taken Private by Concentra Biosciences
- Press ReleaseMay 1, 2025
Goodwin Welcomes Leading Life Sciences and Intellectual Property Partner William T. Christiansen II Ph.D.
- Press ReleaseMay 1, 2025
Goodwin Guides Apnimed in Acquisition of Global Rights to Patents Covering Sulthiame, a Differentiated Carbonic Anhydrase Inhibitor
- Press ReleaseMay 1, 2025
Goodwin Guides Oak Hill Bio in Exclusive Licensing Agreement with Roche to Obtain Global Rights for a Treatment for Individuals with Angelman Syndrome